急性冠脉综合征后双联抗血小板联合口服抗凝药:系统评价与荟萃分析
疗效获益在STEMI患者中显著(OR 0.76),而在NSTE-ACS患者中未观察到显著获益(OR 0.92)。
要点
- ACS后APT加用DOAC可降低心血管死亡、心梗和卒中复合终点风险。
- DOAC使大出血风险增加约3倍,STEMI与NSTE-ACS患者中均一致。
- STEMI患者疗效获益显著,NSTE-ACS患者风险获益比不利。
核心结论
- ACS后APT加用DOAC可显著降低主要疗效终点风险,但显著增加大出血风险;疗效获益在STEMI患者中显著,在NSTE-ACS患者中未观察到显著获益,NSTE-ACS患者风险获益比不利。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Embase、BioMedCentral、Google Scholar和Cochrane Central Register of Controlled Trials从建库至2017年3月1日。
- 使用随机效应模型合并数据,采用Cochrane风险偏倚工具2.0版评估偏倚风险。
关键数值与推荐
- 主要疗效终点为心血管死亡、心肌梗死和卒中的复合终点。
- 主要安全终点为大出血。
- 纳入标准为ACS后使用DOAC的随机临床试验。
临床怎么用
- STEMI患者后APT加用DOAC可能作为有吸引力的选择,但需权衡大出血风险。
- NSTE-ACS患者中DOAC加用APT的风险获益比不利,不推荐常规使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with acute coronary syndrome (ACS) remain at high risk for experiencing recurrent ischemic events. Direct oral anticoagulants (DOAC) have been proposed for secondary prevention after ACS. OBJECTIVE: To evaluate the safety and efficacy of DOAC in addition to antiplatelet therapy (APT) after ACS, focusing on treatment effects stratified by baseline clinical presentation (non-ST-segment elevation ACS [NSTE-ACS] vs ST-segment elevation myocardial infarction [STEMI]). DATA SOURCES: PubMed, Embase, BioMedCentral, Google Scholar, and the Cochrane Central Register of Controlled Trials were searched from inception to March 1, 2017. STUDY SELECTION: Randomized clinical trials on DOAC after ACS were evaluated for inclusion. Overall, 473 studies were screened, 19 clinical trials were assessed as potentially eligible, and 6 were included in the meta-analysis. DATA EXTRACTION AND SYNTHESIS: Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used to abstract data and assess quality and validity. The risk of bias tool, version 2.0 (Cochrane) was used for risk of bias assessment. Data were pooled using random-effects models. MAIN OUTCOMES AND MEASURES: The prespecified primary efficacy end point was the composite of cardiovascular death, myocardial infarction, and stroke. The prespecified primary safety end point was major bleeding. RESULTS: Six trials that included 29 667 patients were identified (14 580 patients [49.1%] with STEMI and 15 036 [50.7%] with NSTE-ACS). The primary efficacy end point risk was significantly lower in patients who were treated with DOAC as compared with APT alone (odds ratio [OR], 0.85; 95% CI, 0.77-0.93; P < .001). This benefit was pronounced in patients with STEMI (OR, 0.76; 95% CI, 0.66-0.88; P < .001), while no significant treatment effect was observed in patients with NSTE-ACS (OR, 0.92; 95% CI, 0.78-1.09; P = .36; P for interaction = .09). With respect to safety, DOACs were associated with a higher risk of major bleeding as compared with APT alone (OR, 3.17; 95% CI, 2.27-4.42; P < .001), with consistent results in patients with STEMI (OR, 3.45; 95% CI, 1.95-6.09; P < .001) and NSTE-ACS (OR, 2.19; 95% CI, 1.38-3.48; P < .001; P for interaction = .23). CONCLUSIONS AND RELEVANCE: To our knowledge, these findings are the first evidence to support differential treatment effects of DOAC in addition to APT according to ACS baseline clinical presentation. In patients with NSTE-ACS, the risk-benefit profile of DOAC appears unfavorable. Conversely, DOAC in addition to APT might represent an attractive option for patients with STEMI.
引用
- Chiarito M, Cao D, Cannata F, et al. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis. JAMA Cardiol. 2018. PMID: 29417147. doi:10.1001/jamacardio.2017.5306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。